Obizur (susoctocog alfa) / Takeda, Ipsen 
Welcome,         Profile    Billing    Logout  
 1 Disease   3 Trials   3 Trials   115 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Obizur (susoctocog alfa) / Takeda, Ipsen
OBI-1, NCT03679455 / 2016-005053-20: A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia,

Recruiting
2
30
Europe
Obinutuzumab 25 MG/ML, Gazyvaro
Polish Myeloma Consortium, Roche Pharma AG, Bioscience, S.A.
Waldenstrom Macroglobulinemia
04/19
12/22
NCT01968655: Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

No Longer Available
N/A
US
OBI-1, B-Domain Deleted Recombinant Porcine Factor VIII
Baxalta now part of Shire
Acquired Hemophilia A
 
 
NCT06461533: A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Recruiting
N/A
25
Japan
Susoctocog Alfa (Genetical Recombination), OBIZUR Intravenous Injection 500, TAK-672
Takeda
Acquired Hemophilia A
10/29
10/29

Download Options